A remarkable result for the largest RCT of Impella in AMI-Shock conducted to date, an order of magnitude larger than prior ones. Demonstrated a meaningful reduction in mortality, overcoming known increases in vascular complications and limb ischemia that comes with the device

NCSI !!!! Congratulations to Jacob & all the Danger investigators! William W. O'Neill American College of Cardiology #ACC24 Thanks to all who trusted us years ago! nejm.org/doi/full/10.10…

Positive trial for Impella-CP in AMI/CS! Especially important in centers resistant to change. Congratulations to the investigators on a job well done!

#ACC24: DANGER-shock MIЯVΛƬ #IC interviews 🎤 Jacob Eifer Møller about the results 📊 of this trial that show that the implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with #STEMI-related cardiogenic shock, though with

What is so special about #DanGerShock ? 🔥 10y of work 💪 ➡️ International trial ✅ 13% ⬇️ all-cause mortality in 180 days using Impella vs standard care alone ➡️Still ⬆️ risk of complications in #MCS group Someone called it a trial of the decade, is it indeed? #ACC24

Join us for a discussion this Thursday night: - Major MCS trials- our journey so far - Interview w/ DanGer Shock PI Prof. Jacob Moller - How will DanGer impact your practice? - Bleeding & vascular complications in a shock patient - Future directions Chuck Simonton

👇VT ablation with Impella support👇 Despite high-dose catecholamines, complete loss of pulsatility observed during VT induction with RV pacing, PVCs, and during VT! Philipp Sommer Christian Sohns Martin Braun Moneeb Khalaph Vanessa Sciacca Alessandro Parlato Maxim Didenko, MD PhD Stephan H. Winnik

It hasn't gotten much attention, but Azerbaijan continues to threaten Armenia and to hold Armenian hostages -- and it may get much worse, as Noubar Afeyan notes.

It's a painful truth that today, when the world remembers the Armenian genocide of 1915, the 120,0000 Armenians of Nagorno Karabakh have fled their homes in fear of a similar nightmare. Read Noubar Afeyan's powerful statement below and his call to free press service, co-founder

How we did it: Impella support (still required levo 10 during case), IVUS after POBA showed NIH, peripheral laser 1.4 (2.0 did not cross first) and 2.0 several passes, NC high pressure, peripheral DCB 4.0x40 for 1 minute, MCS weaned with RHC at the end.

Our analysis of patients in Protect III study who revived Impella assisted high risk PCI * N = 1237 from 46 centers * Vast majority (82.5%) of pts had complex CAD, poor hemodynamics AND comorbidities * most patients had 2 or more risk factors even within each domain * angio,

4-way Stopcock: double-limb perfusion👍 #ECPella

Join us at SCAI for a Scientific Sessions symposia focused on the latest advancements in cardiac care, highlighting Impella Therapy and improving patient outcomes.

Impressive initiation of full cardiac support in a patient with multiple challenges to device delivery. Congratulations to you and your team.

Tim Tebow My patient’s waiting for a heart transplant @ Mayo Clinic Florida. He’s kept alive by a heart pump called impella. AKA “TIMpella.” Thanks 4 being his inspiration. Getting stronger. Would love 4 u to come over & coach him in person! Mayo Clinic Mayo Clinic Transplant Abiomed

Congratulations. Well deserved

Our analysis of patients with chronic kidney disease (first report of dialysis pts) who received Impella assisted HRPCI in Protect III CircInterventions #CirculationIntv #MedTwitter #CardioTwitter 💥Lower eGFR had more severely calcified CAD, greater atherectomy usage but no increased

Congratulations to you and your team on a beautiful Protected PCI case and great angiographic result

congratulations to you and your team for a fantastic Protected PCI result - complex and high risk patient treated with the skills of your team and the technology available to help patients. Great work!

Impella supported #PCI in chronic CKD. Severe renal dysfunction is associated with worse outcomes at 90 days despite low risk of PCI related complications in a high-risk group. Insights from cVAD PROTECT III Study #cardiotwitter #AHAJournals ahajrnls.org/3V4KEfn